The use of ABC family protein inhibitors, in combination with cytotoxic drugs, is expected to result in the maintenance of adequate chemotherapeutic concentrations in cancer cells, which is made possible by the inhibition of ABC proteins. The gene discussed is ABCB6; the disease is cancer.